Biomarker

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, ALS, Biomarker, Research, Acquisition, Patient, Investment

This agreement provides NeuroSense with access to Lonza's unparalleled, state-of-the-art extracellular vesicles expertise and capabilities quickly and on an 'on-demand' basis, without further commitments.

Key Points: 
  • This agreement provides NeuroSense with access to Lonza's unparalleled, state-of-the-art extracellular vesicles expertise and capabilities quickly and on an 'on-demand' basis, without further commitments.
  • NeuroSense will leverage its extensive experience in biomarker utilization in neurodegenerative diseases.
  • Our 'Dev-on-Demand' solution provides NeuroSense with access to expert scientists working in state-of-the-art laboratories for their development activities.
  • The team and platform make Lonza the partner of choice for NeuroSense to identify exosomes-based biomarkers."

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

Retrieved on: 
Tuesday, April 9, 2024
Neurology, Neuroprotection, Element, Conference call, Institutional review board, Cerebrospinal fluid, Survival, Disease, ALS, SPA, Bone marrow, CSF, Data monitoring committee, Webcast, Patient, Protocol, Biomarker, Mortality, Microsoft Exchange Server, Stem cell, DMC, Screening, Agency, Safety, CAFS, Brainstorm, Therapy, Marketing, FDA, BLA, Neuroinflammation, Food, Pharmaceutical industry

NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS). 

Key Points: 
  • (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS).
  • The SPA agreement with the FDA validates the clinical trial protocol and statistical analysis of the planned Phase 3b trial of NurOwn, demonstrating their adequacy for addressing objectives that support a future BLA (Biologics License Application) in ALS.
  • We appreciate the Agency's engagement and guidance during the SPA process and look forward to moving forward with the study."
  • The Phase 3b trial (Study BCT-006-US) will be a two-part, multicenter, study designed to assess the efficacy and safety of NurOwn in patients with ALS.

Sepsis Diagnostics Market Worth $890 million | MarketsandMarkets™.

Retrieved on: 
Monday, April 8, 2024
Sepsis, High, Development, Growth, Fungal infection, Abbott Laboratories, Incidence, Thermo Fisher Scientific, Danaher Corporation, Biomarker, Sysmex Corporation, Evolution, Pulse, Roche, Service, Vanderbilt University Medical Center, EKF Diagnostics, Medical device

Key Market Players of Sepsis Diagnostics Industry:

Key Points: 
  • Key Market Players of Sepsis Diagnostics Industry:
    As of 2023, prominent players in sepsis diagnostics are bioMérieux (France), Becton Dickinson Company (US), Danaher Corporation (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland).
  • Other players include T2 Biosystems (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), among others.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=92673155
    Sepsis Diagnostics Market - Key Benefits of Buying the Report:
    The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share.
  • Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

Sepsis Diagnostics Market Worth $890 million | MarketsandMarkets™.

Retrieved on: 
Monday, April 8, 2024
Sepsis, High, Development, Growth, Fungal infection, Abbott Laboratories, Incidence, Thermo Fisher Scientific, Danaher Corporation, Biomarker, Evolution, Pulse, Roche, Service, Vanderbilt University Medical Center, EKF Diagnostics, Medical device

Key Market Players of Sepsis Diagnostics Industry:

Key Points: 
  • Key Market Players of Sepsis Diagnostics Industry:
    As of 2023, prominent players in sepsis diagnostics are bioMérieux (France), Becton Dickinson Company (US), Danaher Corporation (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland).
  • Other players include T2 Biosystems (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), among others.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=92673155
    Sepsis Diagnostics Market - Key Benefits of Buying the Report:
    The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share.
  • Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Retrieved on: 
Monday, April 8, 2024
ACT, Gene, Biotechnology, Acceleration, LOH, CDX, Risk, Patient, NGS, Biomarker, Research, MSI, DNA, Cancer, Spacecraft, AACR, MRD, Recurrence, FDA, Health, Plasma, Neoplasm, Medicine, Pharmaceutical industry

BURLINGTON, N.C., April 8, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.

Key Points: 
  • The announcement underscores Labcorp's dedication to investing in scientific, diagnostic and laboratory innovations to support its pharmaceutical, biotechnology and clinical research partners in bringing groundbreaking therapies to market.
  • "Our portfolio expansion enhances our integrated services to empower our partners with the solutions and support they need to advance their development programs and make a lasting difference in patients' lives."
  • Labcorp recently announced the commercial availability of Labcorp Plasma Detect, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) MRD solution for research and investigational use.
  • Labcorp's deep scientific expertise and comprehensive solutions include specialized pre-clinical discovery, biomarker and companion diagnostics (CDx) development and post-commercialization capabilities.

Leading Cardiologists from NYU Langone Heart Present Latest Clinical Findings & Research at American College of Cardiology 73rd Annual Scientific Session

Retrieved on: 
Friday, April 5, 2024
Diagnosis, Internal medicine, Ozone, Cardiovascular disease, Eugene Braunwald, System, N95, Blood, Digital, Assistant, Memory, Risk, Diabetes, Inflammation, Patient, Biomarker, Research, Moyamoya disease, Cardiovascular Research, Splenic infarction, NYU, Ischemia, IMR, Particulates, Woman, Heart failure, American College, MPH, CFR, NYU Langone Health, EHR, American Red Cross, Bangladesh Technical Education Board, Air pollution, Data, Osteoarthritis, ACC, CCD, Work, Physician, Medical device

NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.

Key Points: 
  • NEW YORK, April 5, 2024 /PRNewswire/ -- Experts from NYU Langone Heart are presenting their latest clinical findings and research discoveries during the American College of Cardiology (ACC) 2024 Annual Scientific Session & Expo, held April 6 to 8 in Atlanta.
  • "The ACC conference serves as a place for our faculty to explore, learn, and share all the latest advancements in the field.
  • They will also be available for media interviews to discuss innovative and noteworthy scientific developments emerging from the conference.
  • Her research is focused on understanding what makes heart attacks in women unique and the best methods of detection and treatment.

Portable Microfluidic Biofluid Analyzer Patents Available on the Ocean Tomo Bid-Ask Market® Platform

Retrieved on: 
Friday, April 5, 2024
Breast milk, Dentistry, Microfluidics, Patient, Weight loss, Biomarker, Fertility, Pregnancy, Saliva, Urine, IP, POC, Collection, Auction

CHICAGO, April 5, 2024 /PRNewswire-PRWeb/ -- Ocean Tomo, a part of J.S. Held, announces the auction of a Portable Microfluidic Biofluid Analyzer Patents, available as Lot 187, on the Ocean Tomo Bid-Ask Market® platform.

Key Points: 
  • Held, announces the auction of a Portable Microfluidic Biofluid Analyzer via the Ocean Tomo Bid-Ask Market® platform, supporting patent brokerage, patent auctions and patent transactions.
  • CHICAGO, April 5, 2024 /PRNewswire-PRWeb/ -- Ocean Tomo, a part of J.S.
  • Held, announces the auction of a Portable Microfluidic Biofluid Analyzer Patents, available as Lot 187 , on the Ocean Tomo Bid-Ask Market® platform.
  • To request bidder credentials or to receive further information on this portfolio available on the Ocean Tomo Bid-Ask Market® platform, contact Layna Guo at [email protected] or +1 312 327 8179.

ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie

Retrieved on: 
Monday, March 25, 2024
Cloud, RB1, Hydrolysis, Irinotecan, Progression-free survival, Patient, SAN, Biomarker, Research, DNA, Cancer, Cmax, SN-38, Clinical trial, Curie Institute (Paris), Safety, Prodrug, Homologous recombination, ADC, TNBC, Teaching, PEG

Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).

Key Points: 
  • Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).
  • The TOPOLOGY trial is run by Institut Curie (Paris and Saint Cloud, France), with principal investigator Prof. Francois-Clement Bidard .
  • PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC.
  • Institut Curie has 3 sites (Paris, Saint-Cloud and Orsay) with over 3,700 health professionals working on treatment, research and teaching ([email protected]) Information on this clinical trial is available at clinicaltrials.gov, NCT06162351.

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

Retrieved on: 
Monday, March 25, 2024
Plasma, Conference, Tau, Cell, Disease, CSF, Patient, Biomarker, Research, Median, Asian literature, ADAS-Cog, Tau protein, Safety, NK, Amyloid, Pharmaceutical industry

SANTA ANA, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (“NK”) cell therapeutics, today presented additional Phase 1 clinical trial data on the use of its investigational autologous NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the Tau2024 Global Conference in Washington, D.C.

Key Points: 
  • The additional Phase 1 SNK01 trial data suggest clinical activity regarding cognitive function in patients with advanced Alzheimer’s disease in addition to previously disclosed positive effects on amyloid protein and neuroinflammation biomarkers.
  • Cognitive assessments and CSF/plasma pTau217 and pTau181 analyses were performed at baseline and at 1 and 12 weeks after the final dose.
  • “The data presented today demonstrate additional beneficial effects of SNK01 for the treatment of Alzheimer’s disease,” commented Paul Y.
  • While the results were positive, the Phase 1 trial was a dose-escalation trial that only administered four total doses over 11 weeks.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on: 
Saturday, March 23, 2024
Cassava Sciences, Prior, Initiative, Science, District court, Patient, City University, Journal, Biomarker, News, Ext, LLP, Cassava, Complaint, Person, Neurobiology of Aging, Cognition, Safety, Pomerantz, Action Replay, Data management, FDA, Court, Pharmaceutical industry

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.